8AK Stock Chart & Stats
€42.13
-€0.30(-0.64%)
At close: 4:00 PM EDT
€42.13
-€0.30(-0.64%)
Day’s Range― - ―
52-Week Range€23.20 - €48.28
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
€6.79B
Enterprise Value€10.01B
Total Cash (Recent Filing)€656.58M
Total Debt (Recent Filing)€1.57B
Price to Earnings (P/E)112.5
Beta0.71
Next Earnings
Nov 03, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding167,763,280
10 Day Avg. Volume0
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.16Price Target Upside23.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.49
Revenue Forecast (FY)€1.63B
Bulls Say, Bears Say
Bulls Say
Strong Proprietary Product GrowthBroad growth across the proprietary portfolio demonstrates meaningful commercial traction in psychiatry, addiction and sleep medicine. A larger branded revenue base can support continued investment, improve operating leverage over time, and reduce reliance on any single product or partnered revenue stream.
Advancing Orexin PipelinePositive early clinical evidence for ALKS 7290 expands Alkermes’ potential beyond its current commercial portfolio and supports a differentiated orexin strategy. Alongside advancing narcolepsy and idiopathic hypersomnia programs, the pipeline could create additional durable growth options if later-stage results confirm efficacy.
Positive Cash GenerationPositive operating and free cash flow show that the company is converting its commercial platform into internally generated funding. This supports ongoing research, commercialization and debt service while providing greater flexibility than a business dependent primarily on external financing.
Bears Say
Higher LeverageThe sharp increase in leverage raises fixed financial obligations and reduces flexibility if product growth or cash generation weakens. Although equity remains sizable, higher debt can constrain capital allocation and leave fewer resources available for pipeline investment or unexpected operating pressure.
Profitability CompressionThe steep margin decline weakens confidence in the durability of current earnings, even as revenue has returned to modest growth. Lower profitability reduces the cash available for reinvestment and makes the company more sensitive to higher commercialization, development and financing costs.
LYBALVI Gross-to-net PressureRising gross-to-net deductions mean prescription growth may translate into less net revenue and weaker product economics. While broader access can support volume, sustained pricing and reimbursement pressure could limit margin expansion and reduce the contribution of LYBALVI to long-term earnings.
Alkermes News
8AK FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was €23.20 and its highest was €48.28 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is €6.79B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Nov 03, 2026 which is in 2 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Jul 28, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.024 by €0.024.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is -0.07.
How many shares outstanding does Alkermes have?
Alkermes has 167,763,280 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of €0 in its last earnings report, beating expectations of -€0.024. Following the earnings report the stock price went down -1.012%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in DE:8AK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€52.16 (23.81% Upside)
€52.16 (23.81% Upside)
Blogger Sentiment
Bullish
DE:8AK Sentiment 67%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.11%
12-Months-Change
Fundamentals
Return on Equity
3.72%
Trailing 12-Months
Asset Growth
95.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alkermes
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
8AK Company Deck
8AK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical progress, particularly across the orexin franchise and the successful integration of Avadel/LUMRYZ. Key revenue and access wins (proprietary sales +34% YoY, LYBALVI access >80%, LUMRYZ patient growth +25% YoY) and robust pipeline readouts (alixorexton LTE durability, Positive LUMRYZ Phase 3, multiple orexin programs advancing) underpin optimism. Offsetting items include margin pressure from expanding gross-to-net (LYBALVI), a substantial increase in R&D and SG&A tied to pipeline advancement and acquisition integration, a contingent consideration charge that pushes the GAAP loss guidance negative, and competitive/pricing uncertainty from other orexin entrants. Overall, the positive commercial and clinical developments outweigh the cost and near-term margin headwinds.View all DE:8AK earnings summaries8AK Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
8AK Stock 12 Month Forecast
Average Price Target
€52.16
▲(23.81% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Supernus Pharmaceuticals
―
Indivior
―
Takeda Pharmaceutical Company
―